Blueprint Medicines names Christoph Lengauer chief scientific officer

Friday, February 10, 2012 11:44 AM

Blueprint Medicines, a Cambridge, Mass.-based developer of personalized cancer therapies, has appointed Christoph Lengauer, Ph.D., chief scientific officer.

Lengauer most recently was vice president and global head of oncology drug discovery and preclinical development at Sanofi. Previously, he was executive director and senior unit head, oncology discovery at the Novartis Institutes for Biomedical Research, and an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.

Lengauer has a proven track record in cancer drug discovery, including contributing to 17 development candidates, 11 drugs/programs that reached first-in-human clinical trials and two registered drugs. He is lead or senior author of several scientific articles published in journals such as Cell, Nature and Science.

"Christoph has been at the forefront of the development of several novel and effective cancer drugs that have had a significant impact on patients' lives and brings a powerful understanding of cancer drug development to Blueprint," said Nicholas Lydon, Ph.D., scientific co-founder of Blueprint Medicines. "He is uniquely suited to lead our cancer therapeutics development strategy, and we believe his appointment is a true validation of the potential of Blueprint Medicines' platform and our ability to leverage emerging molecular insights to develop genomically-driven, highly selective therapies."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs